Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells

被引:83
作者
Jahrsdörfer, B
Wooldridge, JE
Blackwell, SE
Taylor, CM
Griffith, TS
Link, BK
Weiner, GJ
机构
[1] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA
[3] Univ Iowa, Dept Urol, Iowa City, IA 52242 USA
关键词
B-CLL; cytogenetic status; CpG ODN; caspase;
D O I
10.1189/jlb.0604373
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Immunostimulatory oligodeoxynucleotides (IS ODN) can mediate a number of immunologic effects. We previously demonstrated that treatment of B cell chronic lymphocytic leukemia (B-CLL) cells with one class of IS ODN, CpG ODN, alters their phenotype and increases their immunogenicity. Here, we demonstrate that in contrast to the classic understanding of CpG ODN as inhibitors of B cell apoptosis, IS ODN including CpG ODN induce apoptosis in B-CLL cells. It is important that these changes are seen not only with CpG ODN but with ODN that lack the classical CpG motif. B-CLL cells from 20 subjects were treated in vitro with IS ODN for up to 7 days. IS ODN treatment resulted in increased numbers of apoptotic cells in 13 out of 20 B-CLL samples. IS ODN enhanced apoptosis in samples with 13q deletion as a single aberration and had a heterogeneous effect on apoptosis in samples with other aberrations including 17p deletion, 11q deletion, or trisomy 12. Induction of apoptosis did not correlate with expression of the CpG ODN receptor Toll-like receptor 9. Apoptosis was dependent on the activation of caspases and was accompanied by up-regulation of CD95/Fas and its ligand. We conclude that IS ODN including CpG ODN can induce apoptosis of most B-CLL samples. The ability of IS ODN to induce apoptosis differs based on cytogenetic status. Upregulation of CD95/Fas may play a role in IS ODN-induced apoptosis of B-CLL.
引用
收藏
页码:378 / 387
页数:10
相关论文
共 20 条
[1]   Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia [J].
Anether, G ;
Marschitz, I ;
Tinhofer, I ;
Greil, R .
BLOOD, 2002, 99 (02) :722-723
[2]  
Barton GM, 2002, CURR TOP MICROBIOL, V270, P81
[3]   Maintenance of serological memory by polyclonal activation of human memory B cells [J].
Bernasconi, NL ;
Traggiai, E ;
Lanzavecchia, A .
SCIENCE, 2002, 298 (5601) :2199-2202
[4]   Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia [J].
Chu, P ;
Deforce, D ;
Pedersen, IM ;
Kim, Y ;
Kitada, S ;
Reed, JC ;
Kipps, TJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (06) :3854-3859
[5]   Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells [J].
Decker, T ;
Schneller, F ;
Sparwasser, T ;
Tretter, T ;
Lipford, GB ;
Wagner, H ;
Peschel, C .
BLOOD, 2000, 95 (03) :999-1006
[6]   Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells [J].
Decker, T ;
Peschel, C .
LEUKEMIA & LYMPHOMA, 2001, 42 (03) :301-307
[7]   Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: Costimulation with IL-2 results in a highly immunogenic phenotype [J].
Decker, T ;
Schneller, F ;
Kronschnabl, M ;
Dechow, T ;
Lipford, GB ;
Wagner, H ;
Peschel, C .
EXPERIMENTAL HEMATOLOGY, 2000, 28 (05) :558-568
[8]   Genomic aberrations and survival in chronic lymphocytic leukemia. [J].
Döhner, H ;
Stilgenbauer, S ;
Benner, A ;
Leupolt, E ;
Kröber, A ;
Bullinger, L ;
Döhner, K ;
Bentz, M ;
Lichter, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) :1910-1916
[9]   Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells [J].
Donepudi, M ;
Jovasevic, VM ;
Raychaudhuri, P ;
Mokyr, MB .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2003, 52 (03) :162-170
[10]   Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides [J].
Hartmann, G ;
Krug, A ;
Eigler, A ;
Moeller, J ;
Murphy, J ;
Albrecht, R ;
Endres, S .
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1996, 6 (04) :291-299